Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05952804 · ClinicalTrials.gov registry record · Phase 2
IVIG for Infection Prevention After CAR-T-Cell Therapy
A Phase 2 study of Hematologic Malignancies, sponsored by Fred Hutchinson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 6
- Study locations
NCT05952804 is a Phase 2 study of Hematologic Malignancies that is actively recruiting participants, run by Fred Hutchinson Cancer Center. The registered enrollment target is 150 participants, below the 2,709-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (94% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT05952804, a Phase 2 study of Hematologic Malignancies, is actively recruiting participants, sponsored by Fred Hutchinson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 6
- Study locations
Study Summary
This phase II trial compares the effects of immunoglobulin replacement therapy with a placebo for preventing infectious complications in patients receiving CD19 chimeric antigen receptor (CAR)-T cell therapy. Hypogammaglobulinemia is a common complication in patients who receive CD19 CAR-T cell therapy. This is a condition in which the level of immunoglobulins (antibodies) in the blood is low and the risk of infection is high. Immunoglobulin replacement therapy works by replacing the body's immunoglobulin G (IgG) antibodies with donor blood product derived IgG antibodies that may help prevent infection. IgG antibodies are often depleted as a result of CAR-T therapy. Giving immunoglobulin replacement therapy may prevent infectious complications in patients receiving CD19 CAR-T cell therapy.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Saline
- OTHER Survey Administration
- BIOLOGICAL Immune Globulin Infusion (Human), 10% Solution
- BIOLOGICAL Anti-CD19 CAR T Cells Preparation
Study Locations (6)
California
- City of Hope Cancer Center - Duarte
Florida
- Moffitt Cancer Center - Tampa
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
New York
- Memorial Sloan Kettering Cancer Center - New York
Oregon
- Oregon Health and Science University (OHSU) Knight Cancer Institute - Portland
Washington
- Fred Hutch/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-06-10 |
| Est. Completion | 2028-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05952804
The ClinicalTrials.gov registry entry for NCT05952804 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,709-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (94% lower). The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hematologic Malignancies appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT05952804 reports 6 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05952804 about?
NCT05952804 is a clinical study titled "IVIG for Infection Prevention After CAR-T-Cell Therapy". This phase II trial compares the effects of immunoglobulin replacement therapy with a placebo for preventing infectious complications in patients receiving CD19 chimeric antigen receptor (CAR)-T cell therapy. Hypogammaglobulinemia is a common complication in patients who receive CD19 CAR-T cell ther...
What is the current status of trial NCT05952804?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2024-06-10. Estimated completion is 2028-07-31.
What conditions does trial NCT05952804 study?
This clinical trial studies the following conditions: Hematologic Malignancies.
What interventions are being tested in trial NCT05952804?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Saline (OTHER), Survey Administration (OTHER), Immune Globulin Infusion (Human), 10% Solution (BIOLOGICAL), Anti-CD19 CAR T Cells Preparation (BIOLOGICAL).
Who is sponsoring clinical trial NCT05952804?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05952804 being conducted?
This trial has 6 study locations across California, Florida, Massachusetts, New York, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
RECRUITING · Phase 2
-
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
RECRUITING · Phase 2
-
Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation
RECRUITING · Phase 2
-
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
RECRUITING · Phase 2
-
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
RECRUITING · Phase 2
-
Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies with Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.